Bee Venom Inhibits Prostate Cancer Growth in LNCaP Xenografts via Apoptosis
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
연구목적 : 이 연구는 봉약침의 봉독이 NF-κB 활성억제와 안드로겐 수용체 조절 단백질 및 세포자멸사 조절 단백질의 발현을 통하여 세포자멸사를 유도하고, 전립선 암세포를 이식한 쥐에서의 세포자멸사 유도 효과를 확인함으로써, 봉약침의 봉독이 생체 내에서도 세포자멸사를 유도하여 전립선암에 효과를 나타냄을 확인하고자 하였다. 실험방법 : 세포자멸사의 관찰에는 DAPI, TUNEL staining assay를 시행하였으며, 세포자멸 사 조절 단백질의 변동 관찰에는 western blot analysis를 시행하였고, 세포자멸사와 연관된 NF-κB의 활성 변화를 관찰하기 위해 EMSA를 시행하였다. 결 과 :1. DAPI, TUNEL staining assay 결과 봉독 및 melittin을 처리한 LNCaP 세포 모두에서 세포 자멸사 유도율이 유의한 증가를 나타내었다. 2. LNCaP 세포에 봉독이나 melittin을 처리한 결과, 안드로겐 수용체 조절 단백질 중 p-Akt, COX-2, calpain은 봉독과 melittin 모두에서 유의한 감소를 나타내었고, Akt는 melittin에서 유의한 감소를 나타냈으며, 봉독에서 증가하는 경향을 보였고, MMP-9은 증가하였다. 3. 생체 내에서의 봉독의 항암효과를 확인하기 위해 전립선암세포가 이식된 쥐에 봉독을 처리한 후 암세포의 부피와 무게, 쥐의 체중을 측정한 결과, 봉독을 처리한 군에서 암 세포 부피비율 및 무게는 감소하였고, 쥐의 체중은 증가하였다. 4. 전립선암세포가 이식된 쥐에 봉독을 처리한 결과, NF-κB 활성에서 유의한 감소를 나타 내었다. 5. 전립선암세포가 이식된 쥐에 봉독을 처리한 결과, 세포자멸사 조절 단백질 중 Bax/Bcl-2, p53, caspase-3, caspase-9, calpain은 유의한 증가를, COX-2는 유의한 감소를 나타냈으며, MMP-9는 증가를 나타내었다. 결 론 : 이상의 결과는 봉독이 시험관 내에서 뿐만 아니라 생체 내에서도 NF-κB의 활성을 억제하고 안드로겐 수용체 조절 단백질 및 세포자멸사 조절 단백질의 조절을 통하여 인간 전립선암 세포주인 LNCaP의 세포자멸사를 유도함으로써 전립선암 세포 증식억제 효과 및 호르몬 비의존적인 전립선암으로의 전이를 지연시키는 경향이 있을 것으로 사료되고, 봉독 이 전립선암의 예방과 치료에 효과적으로 활용될 수 있을 것으로 기대된다.
참고문헌 (52)
- American Cancer Society, "Cancer facts and figures", Am Cancer Soc 2001 .CeramideTherapy in Prostate Cancer, 391, pp.42~ (2001)
- Dawson N, "Hormonerefractory prostate cancer: Current issues and treatment options", pp.45~ (1999), Physicians & Scientists Publishing Co., Inc
- Isaacs JT, "Apoptosis: Translating theory to therapy for prostate cancer", J Natl Cancer Inst, 92, pp.1367~1369 (2000)
- Ripple GH, "Wilding G. Drug development in prostate cancer", Semin Oncol, 26, pp.217~226 (1999)
- Green DR, "Apoptotic pathways: Paper wraps stone blunts scissors", Cell, 102, pp.1~4 (2000)
- Cattaneo-Pangrazzi RMC, "Cell cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCyd-Pam-P-FdUrd in DU-145 human prostate cancer cells", JCancer Res Clin Oncol, 126, pp.247~256 (2000)
- Lowe SW, "Apoptosis in cancer", Carcinogenesis, 21, pp.485~495 (2000)
- Wang XZ, "Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy", Cancer Res, 59, pp.5842~5848 (1999)
- Isaacs JT, "The role of androgen in the regulation of programmed cell death", apoptosis in normal and malignant prostatic tissue, 1994, pp.5, 391~400
- Tang DG, "Target to apoptosis: A hopeful weapon for prostate cancer", Prostate, 32, pp.284~293 (1997)
- Lee Hong-sun, "Bee Venom Inhibits LNCaP Cell Proliferation Through Induction of Apoptosis Via Inactivation of NF-κB", 대한침구학회지, 25(2), pp.59~74 (2008), 대한침구학회
- Huggins C, "Studies on prostate cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate", Cancer Res, 1, pp.293~297 (1941)
- Miyamoto H, "Androgen deprivation therapy for prostate cancer: Current status and future prospects", Prostate, 61, pp.332~353 (2004)
- Feldman, B.J, "The development of androgen independent prostate cancer", Nat. Rev. Cancer, 1, pp.34~45 (2001)
- Hiroshi Miyamoto, "Inhibition of the Akt, cyclooxygenase- 2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate ancer", Molecular carcinogenesis, 44, pp.1~10 (2005)
- Chang C, "Androgen receptor: An overview", Crit Rev Eukaryot Gene Expr, 5, pp.97~125 (1995)
- Yang H, "Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells", J Cell Physiol, 217(3), pp.569~576 (2008)
- Lowe SW, "Apoptosis in cancer", Carcinogenesis, 21, pp.48595~ (2000)
- Guseva NV, "Death receptor-induced cell death in prostate cancer", J Cell Biochem, 91, pp.7099~ (2004)
- Gurumurthy S, "Regulation of apoptosis in prostate cancer", Cancer Metastasis Rev, 20, pp.22543~ (2001)
- Kantoff PW, "New agents in the therapy of hormone-refractory patients with prostate cancer", Semin Oncol, 22(Suppl 1), pp.324~ (1995)
- Jemal A, "Cancer statistics", CA Cancer J Clin, 57, pp.43~66 (2007)
- Heinlein CA, "Androgen receptor in prostate cancer", Endocr Rev, 25, pp.276~308 (2004)
- Chang C, "Androgen receptor: An overview", Crit Rev Eukaryot Gene Expr, 5, pp.97~125 (1995)
- Tamura K, "Molecular features of hormonerefractory prostate cancer cells by genomewide gene expression profiles", Cancer Res, 67, pp.5117~5125 (2007)
- W Zhu, "Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells", Biochem Biophys Res Commun, 214, pp.1130~1137 (1995)
- Simon,H.U, "Role of reactive oxygen species (ROS) in apoptosis induction", Apoptosis, 5, pp.415~418 (2000)
- Wyllie,A.H, "The genetic regulation of apoptosis", Curr. Opin. Genet.Dev, 5(1), pp.97~104 (1995)
- Green,D.R, "Mitochondria and Apoptosis", Science, 281, pp.1309~1312 (1998)
- Kerr JFR, "Harmon BV: Apoptosis. Its significance in cancer and cancer therapy", Cancer, 27, pp.2013~2026 (1994)
- Hockenbery D, "Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death", Nature, 348, pp.334~336 (1990)
- Lu QL, "Bcl-2: Role in epithelial differentiation and oncogenesis", Hum Pathol, 27, pp.102~110 (1996)
- Lane DP, "guardian of the genome", Nature, 358(15), pp.53~ (1992)
- Kernohan NM, "Regulation of apoptosis by Bcl-2 and its related proteins: Immunochemical challenges and therapeutic implications", J Pathol, 179, pp.1~3 (1996)
- Yang E, "Molecular thanatopsis:A discourse on the BCL2 family and cell death", Blood, 88, pp.386~401 (1996)
- Kroemer G, "The proto-oncogene Bcl-2 and its role in regulating apoptosis", Nat Med, 3, pp.614~620 (1997)
- Bubendorf L, "Prognostic significance of Bcl-2 in clinically localized prostate cancer", Am J Pathol, 148, pp.1557~1565 (1996)
- Colombel M, "Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers", Am J Pathol, 143, pp.390~400 (1993)
- McDonnell TJ, "Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen- ndependent prostate cancer", Cancer Res, 52, pp.6940~6944 (1992)
- Apakama I, "bcl-2 overexpression combined with p53 protein accumulation correlates with hormone- refractory prostate cancer", Br J Cancer, 74, pp.1258~1262 (1996)
- Hollstein M, "mutations in human cancers", Science, 253, pp.49~53 (1991)
- Bauer JJ, "Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer", J Urol, 156, pp.1511~1516 (1996)
- Moul JW, "Protein expression of p53, bcl-2 and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer", Surgery, 120, pp.159~167 (1996)
- Thornberry,N.A, "Caspases : enemies within", Science, 281, pp.1312~1316 (1998)
- Darmon,A.J, "Activation of the apoptotic proteaseCPP32 by cytotoxic T cell derived granzyme B", Nature, 377, pp.446~448 (1995)
- Stattin P, "Cell proliferation assessed by KI-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer", J Urol, 157, pp.219~222 (1997)
- Wyllie,A.H, "The genetic regulation of apoptosis", Curr. Opin. Genet.Dev, 5(1), pp.97~104 (1995)
- Raj GV, "Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB", Prostate, 61, pp.10513~ (2004)
- Syrovets T, "Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo", J Biol Chem, 280, pp.617080~ (2005)
- Li Y, "Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway", Clin. Cancer Res, 8, pp.236977~ (2002)
- Hye Ji Park, "Melittin inhibits human prostate cancer cell growth through induction of apoptotic cell death", 한국독성학회지, 22(1), pp.31~37 (2006), 한국독성학회
- Park HJ, "Antiarthritic effect of bee venom: inhibition of Inflammation mediator generation by suppression of NF-κB through interaction with p50 subunit", Arthritis Rheum, 50, pp.3504~3515 (2004)
